Clinical trials: Neoplasm, Bronchial
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins…
- Trial name
- NCT05668988
- Testing
- sunvozertinib, Pemetrexed+carboplatin
- Where
- 154 sites in United States, Argentina and 13 more
- Volunteers
- 324 people
- Sponsor
- Dizal Pharmaceuticals
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.
- Trial name
- NCT00832494
- Testing
- DMXAA in combination with carboplatin and paclitaxel
- Volunteers
- 105 people
- Sponsor
- Antisoma Research
Non-Small Cell Lung Cancer
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease.
- Trial name
- LIVIGNO-4 (NCT06236438)
- Testing
- Livmoniplimab, Budigalimab, Pembrolizumab
- Where
- 61 sites in United States, Australia and 10 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Metastatic Non Small Cell Lung Cancer
C-TIL051 in Non-Small Cell Lung Cancer
The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1.
- Trial name
- NCT05676749
- Testing
- C-TIL051
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbelZeta Inc.
Non Small Cell Lung Cancer
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the…
- Trial name
- NCT04495153
- Testing
- Aglatimagene besadenovec
- Where
- 14 sites in United States
- Volunteers
- 90 people
- Sponsor
- Candel Therapeutics, Inc.
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study…
- Trial name
- NCT04818983
- Where
- 95 sites in Japan
- Volunteers
- 470 people
- Sponsor
- Chugai Pharmaceutical
Carcinoma, Non-Small-Cell Lung
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00059722
- Testing
- ZD6474, ZD1839
- Where
- 48 sites in United States, Argentina and 4 more
- Volunteers
- 160 people
- Sponsor
- Genzyme, a Sanofi Company
Non-small Cell Lung Cancer
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell…
- Trial name
- NCT03915951
- Testing
- encorafenib, binimetinib
- Where
- 143 sites in United States, Italy and 3 more
- Volunteers
- 98 people
- Sponsor
- Pfizer
Neoplasms
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
The primary purpose of this sub study is to assess the safety, tolerability and determine recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A*02:01, HLA-A*02:05 and/or HLA A*02:06 positive participants with New York esophageal…
- Trial name
- NCT06048705
- Testing
- GSK3901961, Cyclophosphamide, Fludarabine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 7 people
- Sponsor
- Adaptimmune
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands
The study design is a prospective, non-interventional, observational single arm study. A minimum of 150 patients will be recruited from approximately 30 haematology/oncology sites in the Netherlands.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- OCEAN (NCT02891551)
- Volunteers
- 209 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC).
- Trial name
- NCT00097227
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.
- Trial name
- NCT01168973
- Testing
- Ramucirumab, Docetaxel
- Where
- 231 sites in United States, Argentina and 25 more
- Volunteers
- 1,253 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04267237
- Testing
- Atezolizumab, RO7198457
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following…
- Trial name
- NCT03515837
- Testing
- pembrolizumab, pemetrexed, carboplatin
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02771626
- Testing
- CB-839, Nivolumab
- Where
- 17 sites in United States
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Small Cell Lung Cancer
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC.
- Trial name
- NCT02913443
- Testing
- RO7051790
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.